---
title: "Everest Medicines erhält Zulassung für VELSIPITY in China"
description: "Everest Medicines Ltd. has received approval from the National Medical Products Administration (NMPA) in China for VELSIPITY (etrasimod arginine tablets) to treat adults with moderate to severe active"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275069370.md"
published_at: "2026-02-06T04:01:10.000Z"
---

# Everest Medicines erhält Zulassung für VELSIPITY in China

> Everest Medicines Ltd. has received approval from the National Medical Products Administration (NMPA) in China for VELSIPITY (etrasimod arginine tablets) to treat adults with moderate to severe active ulcerative colitis who have inadequate response, loss of response, or intolerance to conventional therapies or biological agents. The company is preparing for the product launch in China and plans to include it in the national reimbursement list.

Everest Medicines Ltd. hat bekannt gegeben, dass die chinesische Arzneimittelbehörde National Medical Products Administration (NMPA) die Zulassung für VELSIPITY (etrasimod arginine tablets) zur Behandlung von Erwachsenen mit mittelschwerer bis schwerer aktiver Colitis ulcerosa erteilt hat, bei denen eine unzureichende Wirkung, ein Wirkverlust oder eine Unverträglichkeit gegenüber herkömmlichen Therapien oder biologischen Wirkstoffen vorliegt. Das Unternehmen bereitet die Markteinführung in China vor und plant die Aufnahme in die nationale Erstattungsliste. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12017455), on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [159102.CN - Huaan Hang Seng Biotech ETF](https://longbridge.com/en/quote/159102.CN.md)
- [516820.CN - Ping An CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/516820.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [159506.CN - Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF](https://longbridge.com/en/quote/159506.CN.md)
- [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md)
- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [01952.HK - EVEREST MED](https://longbridge.com/en/quote/01952.HK.md)
- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 星展分析师上调评级后 云顶新加坡股价涨逾 3% \| 联合早报网 | 星展集团研究将云顶新加坡的评级上调至 “买入”，目标价为 0.90 元，认为通过回购或发放特别股息等资本回报计划，该股有望提升估值并释放股东价值。云顶新加坡股价上涨 3.25%，报 0.795 元。分析师指出，公司每股净现金超过 0.27  | [Link](https://longbridge.com/en/news/276314423.md) |
| 基石药业-B 的肺癌药物 Sugemalimab 获得英国第二次批准 | 药明康德（CStone Pharmaceuticals）已获得英国批准，将其肺癌药物 sugemalimab 作为单药治疗用于不可切除的 III 期非小细胞肺癌成人患者。这标志着该药物在英国的第二个适应症，得益于 III 期 GEMSTON | [Link](https://longbridge.com/en/news/276549711.md) |
| 蚂蚁集团的支付宝 AI 支付和 AI 健康应用 AQ 在春节期间用户数量均突破 1 亿，反映出 AI 在中国的加速普及 | 蚂蚁集团的支付宝 AI 支付和 AI 健康应用 AQ 在 2026 年春节期间各自超过了 1 亿用户，反映了中国对人工智能的广泛采用。支付宝 AI 支付在一周内处理了超过 1.2 亿笔交易，成为首个达到这一里程碑的人工智能原生支付产品。同时 | [Link](https://longbridge.com/en/news/276585392.md) |
| 丽星邮轮取消香港航行后，愤怒的乘客被晾在一边 | 星梦邮轮因突发技术问题取消了从香港出发的预定航行，导致乘客在漫长等待后感到沮丧。公司提供了重新安排航班的选项或全额退款，并赠送了 200 港元的餐饮券和交通费用补偿。乘客们批评了对这一情况的处理，形容他们的经历就像被当作 “难民”。星梦邮轮 | [Link](https://longbridge.com/en/news/275957717.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.